Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Patients with new onset of disease evidenced by diarrhea (≥ 3 unformed stools within 24 hours), and one or more of the following symptoms of CDAD:~  * abdominal pain or cramps~ * peripheral leukocytosis~ * fever~* C. difficile toxin A or B detected in a stool specimen obtained within 3 days before enrollment by enzyme immunoassay.~* Patients willing to avoid the following medications during the study:~  * oral and intravenous metronidazole~ * oral vancomycin~ * anti-peristaltic drugs~ * opiates (patients on opiates may be included in the study if they were taking opiates prior to enrollment and the dose is not increased during the study)~ * Saccharomyces cerevisiae (baker's yeast)~ * Lactobacillus GG~ * cholestyramine~ * colestipol~Exclusion Criteria:~* Patients with other known causes of diarrhea or colitis (e.g., Shigella, Salmonella, Cryptosporidium parvum, Giardia lamblia, Entamoeba histolytica, inflammatory bowel disease, irritable bowel syndrome, advanced AIDS or chemotherapy for malignancy).~* Patients that commonly have 3 or more stools per day and/or severe abdominal pain in the absence of CDAD.~* Patients with severe lactose intolerance.~* Patients with more than 1 recurrence of CDAD during the 6 months prior to enrollment.~* Patients unable to take oral medications.~* Use within 1 week of enrollment of any drug or therapy with anti-C. difficile activity such as oral or intravenous metronidazole and oral vancomycin. \[Patients that have taken up to 3 doses of metronidazole or vancomycin can be included in the study\].~* Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active.~* Patients who are either clinically unstable (e.g., fulminant disease patients with signs of toxic megacolon, imminent perforation, colectomy or death) or unlikely to live throughout the 31-day duration of the study due to underlying illness.~* History of hypersensitivity to nitazoxanide or vancomycin or any active ingredient in the formulations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).